Jubilant Pharmova announced that the United States Food and Drug Administration (USFDA) has concluded pre-approval inspection (PAI) of the solid dosage formulations facility on August 01, 2025 at Roorkee site, India of Jubilant Generics (‘Company'), a subsidiary of its wholly owned subsidiary Jubilant Pharma.
The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations.
The site's revenue from the US market in the trailing twelve month period (July'24 to June'25) is less than one percent of Jubilant Pharmova revenues in the same period.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."